Home | WuXi AppTec

WuXi AppTec provides R&D & manufacturing services enabling companies in the pharmaceutical & biotech industries worldwide to advance discoveries.

Home | WuXi AppTec

Welcome to WuXi AppTec, your premier partner in advancing discoveries and delivering groundbreaking treatments to patients worldwide. With a commitment to excellence in pharmaceutical, biotech, and medical device industries, we offer a broad portfolio of services to meet your R&D and manufacturing needs.

About Us

At WuXi AppTec, we are dedicated to driving innovation and accelerating the development of life-saving therapies. As a global leader, we provide comprehensive solutions tailored to meet the unique challenges of our clients. With state-of-the-art facilities and a team of experienced professionals, we strive to exceed expectations and make a meaningful impact on global healthcare.

Services

Our diverse range of services includes:

• Analytical testing
• Manufacturing
• Peptide synthesis
• Contract research
• Development and more

Platform

Our cutting-edge platform enables seamless collaboration and integration throughout the drug development process. From discovery to commercialization, we offer innovative solutions to streamline operations and expedite time-to-market.

News

Stay updated with the latest news and developments at WuXi AppTec. From FDA approvals to industry recognitions, we keep you informed about our achievements and milestones.

Careers

Join our dynamic team and embark on a rewarding career journey with WuXi AppTec. Explore opportunities to grow professionally and contribute to groundbreaking innovations in healthcare.

Investors

Discover why WuXi AppTec is a trusted partner for investors seeking long-term value and growth opportunities in the pharmaceutical and biotech sectors. Access financial reports, investor resources, and more.

Contact Us

Connect with us today to learn how WuXi AppTec can empower your organization’s success. Whether you have inquiries about our services or are interested in partnership opportunities, our team is here to assist you.

Language Options: EN | 简 | 繁

Experience the WuXi AppTec advantage and unlock the potential of your projects. Explore our website to learn more about our capabilities and offerings. See more of what WuXi AppTec can do for you.

SEE MORE | SEE MORE | SEE MORE | SEE MORE | SEE MORE

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI™ (lifileucel) for Advanced Melanoma

Philadelphia, PA. February 20, 2024 – WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.

Read more

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Shanghai, China – January 8, 2024 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced the commissioning of its two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company’s Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, addressing the surging global demand for peptide therapeutics.

Read more

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

Shanghai, November 8, 2023 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, received the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a growth advisory & growth opportunity analytics firm.

Read more

• 域名信息

  注册人/机构：Network Solutions,LLC

  注册人邮箱：-

  域名年龄：16年27天（过期时间为2028年02月12日)

• 备案信息

  备案号：沪ICP备10016157号

  名称：上海药明康德新药开发有限公司

  性质：企业

  审核时间：2023-11-06

• 网站信息

  IP：124.238.243.238[]